International Journal of Laboratory HematologyGeneticsPeer-reviewed journal article
Development of a Genomic DNA Reference Material Panel for Thalassemia Genetic Testing
Zhenzhen YiniD, Shoufang QuiD, Chuanfeng HuangiD, Fang CheniD, Jianbiao LiiD, Shiping CheniD, Jingyu YeiD, Ying YangiD, Yu ZhengiD, Xi ZhangiD, Xuexi YangiD, Long-Xu Xie, Jitao WeiiD, Fengxiang WeiiD, Jian GuoiD, Jie HuangiD
Abstract
Thalassemia is one of the most common autosomal recessive inherited diseases worldwide, and it is also highly prevalent and variable in Southern China. Various types of genetic testing technologies have been developed for diagnosis and screening of thalassemia. Characterized genomic DNA reference materials are necessary for assay development, validation, proficiency testing and quality assurance. However, there is no publicly available reference materials for thalassemia genetic testing as yet. To address the need for these materials, the National Institutes for Food and Drug Control and the China National Gene Bank established 31 new cell lines with 2 wild genotypes and 29 distinct genotypes of thalassemia which account for approximately 90% thalassemia carriers in China. The genomic DNA of 31 cell lines were characterized by four clinical genetic testing laboratories using different genetic testing methods and technology platforms. The genotyping results were concordant among four laboratories. In addition, the results of stability test demonstrated that the genotypes of these DNA samples were not influenced by preanalytical conditions such as long-term exposure to high temperature(37{square}) environment and repeated freeze-thawing. In conclusion, we developed the first national panel of 31 genomic DNA reference materials which are renewable and publicly available for the quality assurance of various genetic testing methods and will facilitate research and development in thalassemia genetic testing.
- organism: human
- assay: whole-genome sequencing
- research focus: benchmarking
- approach: statistical model
- Citations
- 5
- FWCI
- 0.13
- Field percentile
- 42th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Creation of an Expert Curated Variant List for Clinical Genomic Test Development and Validation: A ClinGen and GeT-RM Collaborative Project
Emma H. Wilcox, Steven M. Harrison, … Birgit Funke·Journal of Molecular DiagnosticsPeer-reviewed·Aug 9, 2021
- Clinical validity of single-gene non-invasive prenatal testing for sickle cell disease and beta thalassemia
Erik R. Westin, David Tsao, … Vivien Sheehan·medRxiv·Sep 2, 2021
- Clinical testing panels for ALS: global distribution, consistency, and challenges
Allison Ann Dilliott, Ahmad Al Nasser, … On behalf of the Amyotrophic lateral sclerosis spectrum disorders Gene Curation Expert Panel·Amyotrophic Lateral Sclerosis and Frontotemporal DegenerationPeer-reviewed·Mar 10, 2023
- Development, validation and clinical implementation of cellular swab materials for quality assurance of pharmacogenomic point-of-care testing
Henry Thomas, John Henry McDermott, … Rosa Morra·medRxiv·Oct 14, 2026
- The spectrum of rare and novel indel mutations responsible for β Thalassemia in eastern India
Sajan Sinha, Atanu Kumar Dutta, … Mrinal Kanti Das·Indian Journal of Clinical BiochemistryPeer-reviewed·Jan 3, 2023
- Quartet DNA reference materials and datasets for comprehensively evaluating germline variants calling performance
Luyao Ren, Xiaoke Duan, … Yuanting Zheng·Genome biologyPeer-reviewed·Nov 27, 2023